Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PANTHEON: Sequential Chemotherapy in Metastatic Pancreatic Cancer
NCT03331640Phase 2Terminated
- Sponsor
- AIO-Studien
- Start
- Jan 2018
- Primary completion
- Sep 2021
- Modality
- Nanoparticles, Monoclonal Antibodies, DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
A Phase 2 trial of oxaliplatin, irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab, fluorouracil, folinic acid in pancreatic adenocarcinoma (PDAC), sponsored by AIO-Studien. Started Jan 2018; status: terminated.
02
Drugs
oxaliplatinirinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumabfluorouracilfolinic acid
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT03331640.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03331640.